Similar Papers

Paper Title
Journal
Date
Author
Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis.
Wenzhen Ge ... Ning Wu
Future Oncology | VOL. 18
Wenzhen Ge, et. al.Wenzhen Ge ... Ning Wu
23 Jun 2022
Response to "Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis".
Florian Herms ... Nicole Basset-Seguin
Future Oncology | VOL. 19
Florian Herms, et. al.Florian Herms ... Nicole Basset-Seguin
01 Nov 2023
Real-world treatment patterns among patients with diffuse large B-cell lymphoma (DLBCL) treated with CD19-directed chimeric antigen receptor T-cell therapy (CAR T).
Jessica J Jalbert ... Wenzhen Ge
Journal of Clinical Oncology | VOL. 38
Jessica J Jalbert, et. al.Jessica J Jalbert ... Wenzhen Ge
20 May 2020
YAP-TEAD signaling promotes basal cell carcinoma development via a c-JUN/AP1 axis.
Dejan Maglic ... Riccardo Panero
The EMBO Journal | VOL. 37
Dejan Maglic, et. al.Dejan Maglic ... Riccardo Panero
23 Jul 2018
View more papers

More From: Future Oncology

Paper Title
Journal
Date
Author
Impact of APOBEC3s on the occurrence, development and prognosis of esophageal squamous cell carcinoma
Fan Yang ... Nan Dai
Future Oncology | VOL. -
Fan Yang, et. al.Fan Yang ... Nan Dai
30 Dec 2025
BioPearl™ doxorubicin microspheres for unresectable HCC: a prospective, single-arm, multicenter study: BIOPEARL-ONE
Gontran Verset ... Geert Maleux
Future Oncology | VOL. -
Gontran Verset, et. al.Gontran Verset ... Geert Maleux
30 Dec 2025
DRP1: shedding light on the complex nexus of mitochondrial fission and breast cancer
Li You ... Jinbo Liu
Future Oncology | VOL. -
Li You, et. al.Li You ... Jinbo Liu
29 Dec 2025
Efficacy and safety of triple or dual therapies for metastatic hormone-sensitive prostate cancer: a systematic review and Bayesian network meta-analysis
Jingqi Jiang ... Hanzhang Wang
Future Oncology | VOL. -
Jingqi Jiang, et. al.Jingqi Jiang ... Hanzhang Wang
19 Jun 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.